Prima Biomed's (ASX:PRR) results from a phase I clinical trial of its CancerVac MFP technology for advanced adenocarcinoma have been accepted and published in the journal Clinical Cancer Research.

Prima Biomed (ASX:PRR) has received the first payment of US$500,000 from Toronto-based immunology company Trillium Therapeutics following the settlement of the sale of Prima's subsidiary Arthron.

A research report in the international journal Vaccine this month has confirmed the immunity-boosting potency of Prima Biomed's (ASX:PRR) novel DCtag adjuvant technology for veterinary vaccines.

What are the odds that Australians' precious nest eggs be used to invest in something as risky as biotech? Well guess what -- it's already happening, and governments face pressure to free up more superannuation funds, writes Ruth Beran.

Melbourne's Austin Research Institute (ARI) and vaccine developer Panvax have signed an agreement with the Walter Reed Army Institute of Research to develop an experimental malaria vaccine.

Living Cell Technologies (ASX:LCT) has appointed US based neuroscientist Dr Dwaine F Emerich as chief scientific officer of LCT BioPharma. He has been LCT's US vice-president of research since 2003, joining the company from Sertoli Technologies.

Prima Biomed (ASX: PRR) has entered into an agreement to sell all the assets of its subsidiary Arthron to Toronto-based private company Trillium Therapeutics.

AstraZeneca has agreed to extend the completion date for a validation study of Prima Biomed (ASX:PRR) subsidiary Arthron's anti-inflammatory Fc receptor target.

Arthron, a subsidiary of Prima Biomed (ASX:PRR) has signed a license and option agreement with US biotechnology company Xencor to utilise Arthron's Fc receptor technology for enhancing the effect of anti-cancer antibodies.

In the wake of its annual Australian Biotechnology Expo, held earlier this week in Sydney, EG Capital executive director Alison Coutts is optimistic that the Australian biotech sector is on the way back up.

Prima Biomed (ASX:PRR) and the Austin Research Institute (ARI) have reached an in principle agreement enabling Prima to gain full ownership of its four subsidiary companies, Oncomab, Panvax, Cancer Vac and Arthron.